In the following steps, the breast cancer cells were incubated with a specific biotin-conjugated anti-ErbB2-Affibody, fixated with paraformaldehyde to prevent artificial clustering of labels, and marked with fluorescent, streptavidin-conjugated QDs. Here, ERBB2 is linked to breast carcinoma.